BiondVax Pharmaceuticals prices ~$8M underwritten public offering

Immunotherapeutic products company BiondVax Pharmaceuticals (NASDAQ:BVXV) priced an ~$8M underwritten public offering.
The offering consists of 1.6M units and pre-funded units, with each unit consisting of one American Depositary Share and two warrants, each to purchase one ADS. Each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS.
Each ADS (or pre-funded warrant) is being sold together with two warrants at a combined purchase price of $5 per unit (or $4.999 per pre-funded unit after reducing $0.001 attributable to the exercise price of the pre-funded warrants).
Each ADS represents 400 ordinary shares, no par value per share.
The offering is expected to close on Dec. 20.
The net proceeds are expected to be used for the advancement of the company's NanoAbs development program, as well as general corporate purposes.
Source: Press Release